Facilitated and controlled strontium ranelate delivery using gcs-ha nanocarriers embedded into pegda coupled with decortication driven spinal regeneration
Journal
International Journal of Nanomedicine
Journal Volume
16
Pages
4209-4224
Date Issued
2021
Author(s)
Chiang C.-W
Chen C.-H
Manga Y.B
Huang S.-C
Chao K.-M
Jheng P.-R
Wong P.-C
Nyambat B
Satapathy M.K
Chuang E.-Y.
Abstract
Background and Purpose: Strontium ranelate (SrR) is an oral pharmaceutical agent for osteoporosis. In recent years, numerous unwanted side effects of oral SrR have been revealed. Therefore, its clinical administration and applications are limited. Hereby, this study aims to develop, formulate, and characterize an effective SrR carrier system for spinal bone regeneration. Methods: Herein, glycol chitosan with hyaluronic acid (HA)-based nanoformulation was used to encapsulate SrR nanoparticles (SrRNPs) through electrostatic interaction. Afterward, the poly(ethylene glycol) diacrylate (PEGDA)-based hydrogels were used to encapsulate pre-synthesized SrRNPs (SrRNPs-H). The scanning electron microscope (SEM), TEM, rhe-ometer, Fourier-transform infrared spectroscopy (FTIR), and dynamic light scattering (DLS) were used to characterize prepared formulations. The rabbit osteoblast and a rat spinal decortication models were used to evaluate and assess the developed formulation biocompat-ibility and therapeutic efficacy. Results: In vitro and in vivo studies for cytotoxicity and bone regeneration were conducted. The cell viability test showed that SrRNPs exerted no cytotoxic effects in osteoblast in vitro. Furthermore, in vivo analysis for new bone regeneration mechanism was carried out on rat decortication models. Radiographical and histological analysis suggested a higher level of bone regeneration in the SrRNPs-H-implanted groups than in the other experimental groups. Conclusion: Local administration of the newly developed formulated SrR could be a promising alternative therapy to enhance bone regeneration in bone-defect sites in future clinical applications. ? 2021 Chiang et al.
Subjects
Drug formulation
Glycol chitosan
Hyaluronic acid
Nanoparticles
Strontium ranelate
biomaterial
chitosan
glycol
hyaluronic acid
hydrogel
isoflurane
macrogol
molecular scaffold
nanocarrier
nanocomposite
nanoparticle
poly ethylene glycol diacrylate
small nuclear ribonucleoprotein
strontium ranelate
unclassified drug
drug carrier
poly(ethylene glycol)diacrylate
thiophene derivative
anesthesia
animal experiment
animal model
animal tissue
Article
biocompatibility
biological activity
bone defect
bone density
bone regeneration
cell interaction
cell proliferation
cell viability
controlled drug release
controlled study
cytotoxicity
decortication
drug delivery system
drug formulation
drug release
electron microscopy
encapsulation
fluorescence microscopy
Fourier transform infrared spectroscopy
histology
in vitro study
in vivo study
inflammation
infrared spectroscopy
light scattering
male
micro-computed tomography
MTT assay
nonhuman
osteoblast
osteoporosis
rat
scanning electron microscopy
spectroscopy
spinal cord regeneration
transmission electron microscopy
administration and dosage
animal
cell communication
cell survival
chemistry
delayed release formulation
drug effect
Leporidae
particle size
pharmacology
physiology
spine
ultrastructure
Wistar rat
Animals
Bone Regeneration
Cell Communication
Cell Proliferation
Cell Survival
Delayed-Action Preparations
Drug Carriers
Hyaluronic Acid
Hydrogels
Male
Particle Size
Polyethylene Glycols
Rabbits
Rats, Wistar
Spine
Thiophenes
SDGs
Type
journal article